Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

I. Celine Hanson; Tracy A. Antonelli; Rhoda S. Sperling; James M. Oleske; Ellen Cooper; Mary Culnane; Mary Glenn Fowler; Leslie A. Kalish; Sophia S. Lee; George McSherry; Lynne Mofenson; David E. Shapiro

doi:10.1097/00042560-199904150-00008

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

I. Celine Hanson, Tracy A. Antonelli, Rhoda S. Sperling, James M. Oleske, Ellen Cooper, Mary Culnane, Mary Glenn Fowler, Leslie A. Kalish, Sophia S. Lee, George McSherry, Lynne Mofenson, David E. Shapiro

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Abstract

Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as positive in several in vitro carcinogenicity screening tests. We evaluated the short-term risk for tumors in 727 children with known ZDV exposure enrolled into the PACTG 076/219 and the Women and Infants Transmission Study (WITS). ZDV exposure in utero (antepartum) occurred in 97% and 99% of infants in PACTG 076/219 or WITS, respectively. Mean follow-up was 38.3 months with 366.9 person years follow-up for PACTG 076/219 and 14.5 months with 743.7 person years follow- up for WITS. No tumors of any nature were observed; relative risk was 0 (95% confidence interval [CI], 0-17.6). These data are reassuring regarding the short-term lack of tumors for ZDV-exposed infants observed to date. Longitudinal, standardized follow-up for infants with in utero antiretroviral exposure is necessary to assess long-term carcinogenicity.

Original language	English
Pages (from-to)	463-467
Number of pages	5
Journal	Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1097/00042560-199904150-00008
State	Published - 15 Apr 1999

Keywords

Carcinogenesis
Perinatal HIV transmission
Perinatal HIV transmission prophylaxis
Zidovudine

Access to Document

10.1097/00042560-199904150-00008

Cite this

Hanson, I. C., Antonelli, T. A., Sperling, R. S., Oleske, J. M., Cooper, E., Culnane, M., Fowler, M. G., Kalish, L. A., Lee, S. S., McSherry, G., Mofenson, L., & Shapiro, D. E. (1999). Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20(5), 463-467. https://doi.org/10.1097/00042560-199904150-00008

@article{89e08163ce5e48f99d47da3e2dbd6365,

title = "Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine",

abstract = "Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as positive in several in vitro carcinogenicity screening tests. We evaluated the short-term risk for tumors in 727 children with known ZDV exposure enrolled into the PACTG 076/219 and the Women and Infants Transmission Study (WITS). ZDV exposure in utero (antepartum) occurred in 97% and 99% of infants in PACTG 076/219 or WITS, respectively. Mean follow-up was 38.3 months with 366.9 person years follow-up for PACTG 076/219 and 14.5 months with 743.7 person years follow- up for WITS. No tumors of any nature were observed; relative risk was 0 (95% confidence interval [CI], 0-17.6). These data are reassuring regarding the short-term lack of tumors for ZDV-exposed infants observed to date. Longitudinal, standardized follow-up for infants with in utero antiretroviral exposure is necessary to assess long-term carcinogenicity.",

keywords = "Carcinogenesis, Perinatal HIV transmission, Perinatal HIV transmission prophylaxis, Zidovudine",

author = "Hanson, {I. Celine} and Antonelli, {Tracy A.} and Sperling, {Rhoda S.} and Oleske, {James M.} and Ellen Cooper and Mary Culnane and Fowler, {Mary Glenn} and Kalish, {Leslie A.} and Lee, {Sophia S.} and George McSherry and Lynne Mofenson and Shapiro, {David E.}",

year = "1999",

month = apr,

day = "15",

doi = "10.1097/00042560-199904150-00008",

language = "English",

volume = "20",

pages = "463--467",

journal = "Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology",

issn = "1077-9450",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

Hanson, IC, Antonelli, TA, Sperling, RS, Oleske, JM, Cooper, E, Culnane, M, Fowler, MG, Kalish, LA, Lee, SS, McSherry, G, Mofenson, L & Shapiro, DE 1999, 'Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 20, no. 5, pp. 463-467. https://doi.org/10.1097/00042560-199904150-00008

TY - JOUR

T1 - Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

AU - Hanson, I. Celine

AU - Antonelli, Tracy A.

AU - Sperling, Rhoda S.

AU - Oleske, James M.

AU - Cooper, Ellen

AU - Culnane, Mary

AU - Fowler, Mary Glenn

AU - Kalish, Leslie A.

AU - Lee, Sophia S.

AU - McSherry, George

AU - Mofenson, Lynne

AU - Shapiro, David E.

PY - 1999/4/15

Y1 - 1999/4/15

N2 - Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as positive in several in vitro carcinogenicity screening tests. We evaluated the short-term risk for tumors in 727 children with known ZDV exposure enrolled into the PACTG 076/219 and the Women and Infants Transmission Study (WITS). ZDV exposure in utero (antepartum) occurred in 97% and 99% of infants in PACTG 076/219 or WITS, respectively. Mean follow-up was 38.3 months with 366.9 person years follow-up for PACTG 076/219 and 14.5 months with 743.7 person years follow- up for WITS. No tumors of any nature were observed; relative risk was 0 (95% confidence interval [CI], 0-17.6). These data are reassuring regarding the short-term lack of tumors for ZDV-exposed infants observed to date. Longitudinal, standardized follow-up for infants with in utero antiretroviral exposure is necessary to assess long-term carcinogenicity.

AB - Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as positive in several in vitro carcinogenicity screening tests. We evaluated the short-term risk for tumors in 727 children with known ZDV exposure enrolled into the PACTG 076/219 and the Women and Infants Transmission Study (WITS). ZDV exposure in utero (antepartum) occurred in 97% and 99% of infants in PACTG 076/219 or WITS, respectively. Mean follow-up was 38.3 months with 366.9 person years follow-up for PACTG 076/219 and 14.5 months with 743.7 person years follow- up for WITS. No tumors of any nature were observed; relative risk was 0 (95% confidence interval [CI], 0-17.6). These data are reassuring regarding the short-term lack of tumors for ZDV-exposed infants observed to date. Longitudinal, standardized follow-up for infants with in utero antiretroviral exposure is necessary to assess long-term carcinogenicity.

KW - Carcinogenesis

KW - Perinatal HIV transmission

KW - Perinatal HIV transmission prophylaxis

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0033560997&partnerID=8YFLogxK

U2 - 10.1097/00042560-199904150-00008

DO - 10.1097/00042560-199904150-00008

M3 - Article

C2 - 10225228

AN - SCOPUS:0033560997

SN - 1077-9450

VL - 20

SP - 463

EP - 467

JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

IS - 5

ER -

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

Abstract

Keywords

Access to Document

Fingerprint

Cite this